Genome Sequences of Brucella melitensis, Isolated from Blood Samples of Brucellosis Patients in Malaysia

Zahidi, Jama’ayah Mohamed; Ahmad, Norazah; Tay, Bee Yong; Hashim, Rohaidah; Khoo, Evie; Ahmad, Nurizan; Yee, Chung Yan; Dolhan, Nur Qhaledaziea

doi:10.1128/genomea.00689-17

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human B. canis infections have been described in Europe, North and South America [ 56 , 60 , 61 ], Hawaii [ 62 ], Japan [ 63 ], China [ 64 ], and Malaysia [ 65 ]. In Europe, only recently, human cases of B. canis -caused brucellosis were reported in the Netherlands – a 55-year-old kennel owner without non-specific clinical symptoms [ 24 ]; in Germany – a 30-year-old female patient with recurrent fever and so-called granulomatous hepatitis and splenomegaly [ 66 ]; and in the UK – a 61-year-old woman who contracted an infection with clinical symptoms from an imported dog, leading to hospitalization for more than 2 weeks [ 67 ].…”

Section: Risks For Human Healthmentioning

confidence: 99%

The emergence of Brucella canis as a public health threat in Europe: what we know and what we need to learn

Djokic,

Freddi,

de Massis

et al. 2023

Emerging Microbes & Infections

View full text Add to dashboard Cite

The zoonotic bacteria, Brucella canis , is becoming the leading cause of canine brucellosis in Europe. In dogs, it causes reproductive problems as well as non-specific lameness or discospondilitis. In humans, B. canis can be origin of chronic debilitating conditions characteristic to its genus such as undulant fever, splenomegaly, and lymphadenopathy. Although B. canis shows some pathogenic characteristics similar to B. abortus and B. melitensis , it lacks surface O-polysaccharide, like nonzoonotic B. ovis . This review shows that host– B. canis interactions are still poorly understood, with many knowledge and capability gaps, causing relatively poor sensitivity and specificity of existing diagnostic tools. Currently, there is no vaccine for this rough Brucella species. Besides, antimicrobial therapy does not guarantee bacterial elimination, and infection relapses are frequently reported, increasing the risks of antibiotic resistance development. B. canis has been detected in dogs in almost all European countries which increased human exposure, but currently there is no systematic surveillance. Moreover, B. canis caused brucellosis is not included in Animal Health Law, and therefore there is no legal framework to tackle this emerging infectious disease. To map out the diagnostic strategies, identify risks for human infections and propose management scheme for infected pet and kennel dogs, we present current understanding of canine B. canis caused brucellosis, outline major knowledge gaps and propose future steps. To address and highlight challenges veterinary and public health services encounter in Europe, we developed two B. canis infection scenarios: of a single household pet and of a kennel dog in larger group.

show abstract

Section: Risks For Human Healthmentioning

confidence: 99%

The emergence of Brucella canis as a public health threat in Europe: what we know and what we need to learn

Djokic,

Freddi,

de Massis

et al. 2023

Emerging Microbes & Infections

View full text Add to dashboard Cite

show abstract

“…Brucella melitensis as one of the Brucella bacteria strains leads to the most cases of human brucellosis which is found in sheep and goat (Mohamed Zahidi et al., 2017; Tadepalli et al., 2016). This infection is transmitted to humans through direct contact or the consumption of unpasteurized products from infected animals (Wareth et al., 2014).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the immunogenicity and efficacy of a chimeric OMP25–OMP31 antigen in BALB/c mice

Mohammadi

2021

Veterinary Medicine & Sci

View full text Add to dashboard Cite

Brucellosis is a zoonotic disease causes by Brucella bacteria. So far, there is not any efficient treatment for this infectious disease in animals, although subunit vaccines can be a safe alternative. To this aim, we have designed a new chimeric OMP25‐OMP31 antigen formulated in Chitosan nanoparticles and studied its protective efficiency in vivo. OMP25–OMP31 was produced using spliced overlap extension by polymerase chain reaction and the 3D protein structure and antigenic ability were predicted using computational tools. In addition, the humoural and cellular immune responses were measured by ELISA in six different experimental groups. The immune response showed chimeric rOMP25–OMP31 antigen‐induced higher titers of IFN‐γ and TNF‐α cytokines, while the lowest amount of IL‐4 was dedicated to itself. Also, rOMP25–OMP31 stimulated higher titer of IgG than individual injection of rOMP25 and rOMP31 treatments and the cell proliferation assay demonstrated the vaccination with rOMP25–OMP31 elicits a vigorous antigen‐specific cell proliferative. In addition, the challenge experiment showed immunised mic stimulated a higher level of protection than negative controls. Overall, the results of rOMP25–OMP31 could be promising for considering chimeric constructs as a feasible vaccine candidate for further investigations against brucellosis.

show abstract

Molecular epidemiology of brucellosis in Asia: insights from genotyping analyses

Ali,

Mushtaq,

Hassan

et al. 2024

Vet Res Commun

View full text Add to dashboard Cite

Genome Sequences of Brucella melitensis, Isolated from Blood Samples of Brucellosis Patients in Malaysia

Abstract: Human brucellosis is a neglected zoonotic disease and has widespread geographical distribution. Brucella melitensis has caused outbreaks and sporadic cases in Malaysia. Here, we present the whole-genome sequences of four B. melitensis strains isolated from brucellosis patients in Malaysia.

Cited by 3 publications

References 7 publications

The emergence of Brucella canis as a public health threat in Europe: what we know and what we need to learn

The emergence of Brucella canis as a public health threat in Europe: what we know and what we need to learn

Evaluation of the immunogenicity and efficacy of a chimeric OMP25–OMP31 antigen in BALB/c mice

Molecular epidemiology of brucellosis in Asia: insights from genotyping analyses

Contact Info

Product

Resources

About